MedTrace Logo

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

NCT05743985 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-02-27

No results posted yet for this study

Summary

The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.

The main questions it aims to answer are:

* What effect, if any, does daily oral consumption of 50mg of full spectrum CBG have on the mental, physical, and emotional wellbeing of healthy individuals, as measured by self-report Medical Symptom Questionnaire and 36-Item Short Form Health Survey scores?
* Is CBG effective at reducing inflammation in the body, as measured by HSCRP, ESR, and PSA inflammatory markers?
* Do age, gender, weight, or state of body inflammation have an effect on the perceived efficacy of CBG?
* What adverse effects, if any, are associated with CBG use?

Over the course of the 12-week study, participants will:

* Take baseline MSQ and SF-36 surveys, as well as a clinical visit with blood draws for HSCRP, ESR, and PSA testing
* Consume one (1) 50mg capsule of full spectrum CBG daily by mouth with food for 8 weeks, followed by a 4-week washout period
* Complete biweekly SF-36 surveys as well as MSQ surveys every 4 weeks
* Attend a clinical visit every 4 weeks for clinical observation and blood draws for HSCRP, ESR, and PSA (male subjects)

Conditions

  • Health, Subjective
  • Inflammatory Response
  • Adverse Effect
  • Side Effect

Interventions

OTHER

Cannabigerol

Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.

Sponsors & Collaborators

  • Formula30A LLC

    lead INDUSTRY

Principal Investigators

  • Cory Rice, D.O. · Modern Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-31
Completion
2024-04-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05743985 on ClinicalTrials.gov